Display options
Cite
Han K, Meng W, Zhang JJ, et al. Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. Onco Targets Ther. 2016;9:3085-94doi: 10.2147/OTT.S102862.
Han, K., Meng, W., Zhang, J. J., Zhou, Y., Wang, Y. L., Su, Y., Lin, S. C., Gan, Z. H., Sun, Y. N., & Min, D. L. (2016). Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. OncoTargets and therapy, 93085-94. https://doi.org/10.2147/OTT.S102862
Han, Kun, et al. "Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301." OncoTargets and therapy vol. 9 (2016): 3085-94. doi: https://doi.org/10.2147/OTT.S102862
Han K, Meng W, Zhang JJ, Zhou Y, Wang YL, Su Y, Lin SC, Gan ZH, Sun YN, Min DL. Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. Onco Targets Ther. 2016 May 26;9:3085-94. doi: 10.2147/OTT.S102862. eCollection 2016. PMID: 27307749; PMCID: PMC4888721.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2016 May 26;9:3085-94. doi: 10.2147/OTT.S102862. eCollection 2016.

Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301.

OncoTargets and therapy

Kun Han, Wei Meng, Jian-Jun Zhang, Yan Zhou, Ya-Ling Wang, Yang Su, Shu-Chen Lin, Zhi-Hua Gan, Yong-Ning Sun, Da-Liu Min

Affiliations

  1. Oncology Department, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China.
  2. Institute of Genetic Engineering of Southern Medical University, Guangzhou, Guangdong, People's Republic of China.

PMID: 27307749 PMCID: PMC4888721 DOI: 10.2147/OTT.S102862

Abstract

Luteolin is a falvonoid compound derived from Lonicera japonica Thunb. Numerous reports have demonstrated that luteolin has anticancer effects on many kinds of tumors. This study investigated the effects of luteolin on prostate cancer (PCa), assessing the PC3 and LNCaP cells. The cell viability and apoptosis were assessed by performing Cell Counting Kit-8 assay and Annexin V-fluorescein isothiocyanate/propidium iodide double staining. Luteolin was found to inhibit androgen-sensitive and androgen-independent PCa cell lines' growth and induced apoptosis. To uncover the exact mechanisms and molecular targets, microRNA (miR) array analysis was performed. miR-301 was found to be markedly downregulated. Then, the expression of miR-301 was retrospectively analyzed in the primary PCa tissues by quantitative reverse transcription polymerase chain reaction and in situ hybridization methods. According to the quantitative reverse transcription polymerase chain reaction results of miR-301, the 54 PCa patients were divided into two groups: high and low miR-301 groups. The division indicator is a relative expression ≥5. Compared to the low-expression group, high miR-301 expression was associated with a significantly shorter overall survival (P=0.029). The proapoptotic gene, DEDD2, was predicted to be the direct target of miR-301. It was clarified in accordance with bioinformatics and luciferase activity analyses. The overexpression of miR-301 by plasmid decreased the luteolin effect. Taken together, these results suggest that luteolin inhibits PCa cell proliferation through miR-301, the poor predictive factor of PCa.

Keywords: DEDD2; apoptosis; luteolin; miR-301; prostate cancer

References

  1. Br J Pharmacol. 2014 Jun;171(11):2842-53 - PubMed
  2. Nat Prod Res. 2016 Jun;30(12 ):1366-72 - PubMed
  3. Eur J Med Chem. 2009 Feb;44(2):908-14 - PubMed
  4. Int J Urol. 2015 Mar;22(3):242-52 - PubMed
  5. J Biol Chem. 2010 Nov 5;285(45):34557-65 - PubMed
  6. PLoS One. 2015 Jun 18;10 (6):e0130599 - PubMed
  7. JAMA Oncol. 2015 Jul;1(4):505-27 - PubMed
  8. Cancers (Basel). 2015 Aug 24;7(3):1643-57 - PubMed
  9. Oncogene. 2003 Jan 16;22(2):291-7 - PubMed
  10. Pharmacogn Mag. 2015 Jul-Sep;11(43):627-35 - PubMed
  11. Nutr Cancer. 2015;67(2):238-49 - PubMed
  12. PLoS One. 2014 Jun 27;9(6):e100124 - PubMed
  13. PLoS One. 2012;7(8):e43304 - PubMed
  14. Sci Rep. 2015 Jul 23;5:12464 - PubMed
  15. J Agric Food Chem. 2015 Apr 29;63(16):4148-59 - PubMed
  16. Food Chem Toxicol. 2012 Nov;50(11):4136-43 - PubMed
  17. Mini Rev Med Chem. 2015;15(6):479-89 - PubMed
  18. Oncotarget. 2013 Feb;4(2):329-45 - PubMed
  19. Mol Med Rep. 2015 Sep;12(3):4196-202 - PubMed
  20. J Transl Med. 2015 Feb 01;13:42 - PubMed
  21. Curr Pharm Biotechnol. 2014;14(12):1009-15 - PubMed
  22. Nihon Rinsho. 2014 Dec;72(12):2097-102 - PubMed
  23. Int J Oncol. 2014 Mar;44(3):725-34 - PubMed
  24. Int J Mol Med. 2011 Jul;28(1):25-31 - PubMed
  25. Chem Biol Interact. 2014 Apr 25;213:60-8 - PubMed
  26. J Pharmacol Exp Ther. 2011 Sep;338(3):1013-22 - PubMed
  27. Biol Pharm Bull. 2015;38(5):703-9 - PubMed
  28. Magy Onkol. 2015 Sep;59(3):229-40 - PubMed
  29. PLoS One. 2014 Oct 13;9(10):e109655 - PubMed
  30. Technol Cancer Res Treat. 2015 Dec;14(6):747-55 - PubMed
  31. Can J Urol. 2014 Apr;21(2 Supp 1):57-63 - PubMed
  32. Cancer Res. 2011 Apr 15;71(8):2926-37 - PubMed
  33. Mol Cancer Ther. 2012 Mar;11(3):660-9 - PubMed
  34. Bioorg Med Chem Lett. 2014 Oct 1;24(19):4672-7 - PubMed

Publication Types